<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086228</url>
  </required_header>
  <id_info>
    <org_study_id>09-384</org_study_id>
    <nct_id>NCT01086228</nct_id>
  </id_info>
  <brief_title>XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan</brief_title>
  <official_title>XIENCE V/PROMUS Everolimus-Eluting Stent System Japan Post-marketing Surveillance Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this post-marketing surveillance, conducted in Japan, is to know the
      frequency, type and degree of device malfunction, to assure the safety of the medical device,
      and to collect information on evaluation of the efficacy and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The surveillance is to be conducted in accordance with the Japanese Ministerial Ordinance
      concerning the Standards for Postmarketing Surveillance and Tests of Medical Devices.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Stent Thrombosis (ST) as Per ARC Definition</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
    <description>Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
Probable ST may occur due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST&amp;in the absence of any other obvious cause.
Possible ST occurred with any unexplained death from 30 days after intracoronary stenting until end of trial follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Stent Thrombosis (ST) as Per ARC Definition</measure>
    <time_frame>From 1 Year to 2 Years</time_frame>
    <description>Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
Probable ST may occur due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST&amp;in the absence of any other obvious cause.
Possible ST occurred with any unexplained death from 30 days after intracoronary stenting until end of trial follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Stent Thrombosis (ST) as Per ARC Definition</measure>
    <time_frame>From 2 years to 3 years</time_frame>
    <description>Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
Probable ST may occur due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST&amp;in the absence of any other obvious cause.
Possible ST occurred with any unexplained death from 30 days after intracoronary stenting until end of trial follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Related to Anti-platelet Medication</measure>
    <time_frame>From post-procedure to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Related to Anti-platelet Medication</measure>
    <time_frame>From 1 year to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Related to Anti-platelet Medication</measure>
    <time_frame>From 2 years to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Related to Anti-platelet Medication</measure>
    <time_frame>From 3 years to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Related to Anti-platelet Medication</measure>
    <time_frame>From 4 years to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>Baseline</time_frame>
    <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>On day 0 after procedure</time_frame>
    <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>At 8 months</time_frame>
    <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Gain</measure>
    <time_frame>On day 0 after procedure</time_frame>
    <description>The acute gain was defined as the difference between post- and pre procedural minimal lumen diameter (MLD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Loss</measure>
    <time_frame>On day 0 after procedure</time_frame>
    <description>Proximal and distal late loss was calculated by [post-procedure minimum lumen diameter (MLD)] - [MLD at 8 months].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Gain</measure>
    <time_frame>On day 0 after procedure</time_frame>
    <description>Net Gain = Acute Gain - Late Loss, paired analysis only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Success</measure>
    <time_frame>On day 0 (Immediately post-index procedure)</time_frame>
    <description>Acute Success: Procedural Success (Subject Level Analysis): Stent implant procedure was considered successful when all of the following criteria were met:
Stent was successfully delivered to the intended location
Stent was successfully deployed at the intended location
Stent delivery system was withdrawn without any issue Stent implantation procedure was considered successful in 99.94% of the stents. There was no stent adjudicated as procedure failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Death (Cardiac Death, Vascular Death, or Non-cardiovascular Death)</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Death (Cardiac Death, Vascular Death, or Non-cardiovascular Death)</measure>
    <time_frame>From 1 to 2 years</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Death (Cardiac Death, Vascular Death, or Non-cardiovascular Death)</measure>
    <time_frame>From 2 years to 3 years</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarctions (MI)</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarctions (MI)</measure>
    <time_frame>From 1 year to 2 years</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarctions (MI)</measure>
    <time_frame>From 2 years to 3 years</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>From 1 year to 2 years</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>From 2 years to 3 years</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>From 1 Year to 2 Years</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>From 2 Years to 3 Years</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death and All MI</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death and All MI</measure>
    <time_frame>From 1 Year to 2 Years</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death and All MI</measure>
    <time_frame>From 2 Years to 3 Years</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Lesion Revascularization (CI-TLR)</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Lesion Revascularization (CI-TLR)</measure>
    <time_frame>From 1 Year to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Lesion Revascularization (CI-TLR)</measure>
    <time_frame>From 2 Years to 3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death, Target Vessel Myocardial Infarction (TVMI) and TLR</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death, Target Vessel Myocardial Infarction (TVMI) and TLR</measure>
    <time_frame>From 1 Year to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death, Target Vessel Myocardial Infarction (TVMI) and TLR</measure>
    <time_frame>From 2 Years to 3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Vessel Revascularization (CI-TVR)</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Vessel Revascularization (CI-TVR)</measure>
    <time_frame>From 1 Year to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Vessel Revascularization (CI-TVR)</measure>
    <time_frame>From 2 Years to 3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths and All MI</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths and All MI</measure>
    <time_frame>From 1 Year to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths and All MI</measure>
    <time_frame>From 2 Years to 3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths, All MI and All Revascularization</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths, All MI and All Revascularization</measure>
    <time_frame>From 1 Year to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths, All MI and All Revascularization</measure>
    <time_frame>From 2 Years to 3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths, TVMI and TLR</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths, TVMI and TLR</measure>
    <time_frame>From 1 Year to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths, TVMI and TLR</measure>
    <time_frame>From 2 Years to 3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths, TVMI and CI-TLR</measure>
    <time_frame>Post Procedure to 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths, TVMI and CI-TLR</measure>
    <time_frame>From 1 Year to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Deaths, TVMI and CI-TLR</measure>
    <time_frame>From 2 Years to 3 Years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2010</enrollment>
  <condition>Angina</condition>
  <condition>Chronic Coronary Occlusion</condition>
  <condition>Stent Thrombosis</condition>
  <condition>Vascular Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>XIENCE V / PROMUS stent</arm_group_label>
    <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE V / PROMUS stent</intervention_name>
    <description>Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
    <arm_group_label>XIENCE V / PROMUS stent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Only patients in Japan, who are eligible to receive treatment for coronary arteries using
        the XIENCE V / PROMUS Everolimus-Eluting Stent System are to be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only XIENCE V stent(s)or PROMUS stent(s) is (are) implanted in the coronary
             vasculature during the index procedure.

        Exclusion Criteria:

          -  Neither XIENCE V stent(s) nor PROMUS stent(s) is (are) implanted in the coronary
             vasculature during the index procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Thompson</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Vascular</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104727</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 113428</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 115745</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104424</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 113645</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105015</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105148</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105177</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104677</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104365</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105038</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105043</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104236</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105963</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104326</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104606</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104607</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104528</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104536</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator#104563</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104837</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104838</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104843</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104844</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104850</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104658</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104990</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105027</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105296</name>
      <address>
        <city>Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104864</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104898</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104906</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 114863</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104407</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 106044</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104697</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104356</name>
      <address>
        <city>Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105092</name>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104448</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104454</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104473</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104497</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104510</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104514</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator#104481</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 104285</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104294</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <results_first_submitted>February 13, 2017</results_first_submitted>
  <results_first_submitted_qc>August 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 19, 2018</results_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting stents</keyword>
  <keyword>Stents</keyword>
  <keyword>Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 2010 patients were registered. Of which 1 patient was excluded from this analysis. Therefore, 2009 patients (1,159 patients treated with XIENCE V; 850 patients treated with PROMUS) were included in the analysis.</recruitment_details>
      <pre_assignment_details>Study has excluded those patients who were treated with stents other than CoCr-EES (XIENCE V or PROMUS), or underwent concomitant treatment of a graft vessel. Patients were invited to enroll in the study after apparently successful per-cutaneous coronary intervention (PCI).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>XIENCE V / PROMUS Stent</title>
          <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>8 Month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2009">Analysis population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1938"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>1-year Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1938"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1894"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2-year Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1894"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1834"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>3-year Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1834"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1767"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>4-year Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1767"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1664"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>5-year Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1664"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1012"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="652"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics were analyzed for 2,009 patients (XIENCE V:1,159 ; PROMUS : 850).</population>
      <group_list>
        <group group_id="B1">
          <title>XIENCE V / PROMUS Stent</title>
          <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2009"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="481"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Stent Thrombosis (ST) as Per ARC Definition</title>
        <description>Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
Probable ST may occur due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST&amp;in the absence of any other obvious cause.
Possible ST occurred with any unexplained death from 30 days after intracoronary stenting until end of trial follow-up</description>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis (ST) as Per ARC Definition</title>
          <description>Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
Probable ST may occur due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST&amp;in the absence of any other obvious cause.
Possible ST occurred with any unexplained death from 30 days after intracoronary stenting until end of trial follow-up</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite Stent Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable Stent Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible Stent Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Stent Thrombosis (ST) as Per ARC Definition</title>
        <description>Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
Probable ST may occur due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST&amp;in the absence of any other obvious cause.
Possible ST occurred with any unexplained death from 30 days after intracoronary stenting until end of trial follow-up</description>
        <time_frame>From 1 Year to 2 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis (ST) as Per ARC Definition</title>
          <description>Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
Probable ST may occur due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST&amp;in the absence of any other obvious cause.
Possible ST occurred with any unexplained death from 30 days after intracoronary stenting until end of trial follow-up</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1894"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite Stent Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable Stent Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible Stent Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Stent Thrombosis (ST) as Per ARC Definition</title>
        <description>Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
Probable ST may occur due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST&amp;in the absence of any other obvious cause.
Possible ST occurred with any unexplained death from 30 days after intracoronary stenting until end of trial follow-up</description>
        <time_frame>From 2 years to 3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis (ST) as Per ARC Definition</title>
          <description>Definite ST occurred by either angiographic/pathologic confirmation of ST.
Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&amp;presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes
Typical rise&amp;fall in cardiac biomarkers
Non-occlusive &amp;occlusive thrombus
Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.
Probable ST may occur due to:
Unexplained death within first 30 days
Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST&amp;in the absence of any other obvious cause.
Possible ST occurred with any unexplained death from 30 days after intracoronary stenting until end of trial follow-up</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1834"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite Stent Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable Stent Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible Stent Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Related to Anti-platelet Medication</title>
        <time_frame>From post-procedure to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Related to Anti-platelet Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal Non-Cardiac Lab Value/Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancer/Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastro-intestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General/Musculoskeletal/Connective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genito-urinary and renal disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological/Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Related to Anti-platelet Medication</title>
        <time_frame>From 1 year to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Related to Anti-platelet Medication</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1894"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal Non-Cardiac Lab Value/Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancer/Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastro-intestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General/Musculoskeletal/Connective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genito-urinary and renal disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological/Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Related to Anti-platelet Medication</title>
        <time_frame>From 2 years to 3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Related to Anti-platelet Medication</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1834"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal Non-Cardiac Lab Value/Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancer/Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastro-intestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General/Musculoskeletal/Connective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genito-urinary and renal disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological/Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Related to Anti-platelet Medication</title>
        <time_frame>From 3 years to 4 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Related to Anti-platelet Medication</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1767"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal Non-Cardiac Lab Value/Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancer/Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastro-intestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General/Musculoskeletal/Connective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genito-urinary and renal disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological/Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Related to Anti-platelet Medication</title>
        <time_frame>From 4 years to 5 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Related to Anti-platelet Medication</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal Non-Cardiac Lab Value/Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancer/Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastro-intestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General/Musculoskeletal/Connective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genito-urinary and renal disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological/Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis (%DS)</title>
        <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
        <time_frame>Baseline</time_frame>
        <population>Pre-procedure and immediate post-procedure angiograms were available from all of the analysis population of 2,009 patients (2,647 lesions), of which 1,850 lesions in 1548 patients were assessed by the core laboratory.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis (%DS)</title>
          <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
          <population>Pre-procedure and immediate post-procedure angiograms were available from all of the analysis population of 2,009 patients (2,647 lesions), of which 1,850 lesions in 1548 patients were assessed by the core laboratory.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1548"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1850"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis (%DS)</title>
        <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
        <time_frame>On day 0 after procedure</time_frame>
        <population>Pre-procedure and immediate post-procedure angiograms were available from all of the analysis population of 2,009 patients (2,647 lesions), of which 1,850 lesions in 1548 patients were assessed by the core laboratory.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis (%DS)</title>
          <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
          <population>Pre-procedure and immediate post-procedure angiograms were available from all of the analysis population of 2,009 patients (2,647 lesions), of which 1,850 lesions in 1548 patients were assessed by the core laboratory.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1548"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1850"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis (%DS)</title>
        <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
        <time_frame>At 8 months</time_frame>
        <population>Eight-month follow-up angiograms for 1,309 lesions in 1,085 patients were assessed by the core laboratory.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis (%DS)</title>
          <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
          <population>Eight-month follow-up angiograms for 1,309 lesions in 1,085 patients were assessed by the core laboratory.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1085"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Gain</title>
        <description>The acute gain was defined as the difference between post- and pre procedural minimal lumen diameter (MLD).</description>
        <time_frame>On day 0 after procedure</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Gain</title>
          <description>The acute gain was defined as the difference between post- and pre procedural minimal lumen diameter (MLD).</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1548"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1850"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In-stent (n=1845 lesions)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.769" lower_limit="1.744" upper_limit="1.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-segment (n=1846 lesions)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.409" lower_limit="1.383" upper_limit="1.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Loss</title>
        <description>Proximal and distal late loss was calculated by [post-procedure minimum lumen diameter (MLD)] – [MLD at 8 months].</description>
        <time_frame>On day 0 after procedure</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Late Loss</title>
          <description>Proximal and distal late loss was calculated by [post-procedure minimum lumen diameter (MLD)] – [MLD at 8 months].</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1548"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1850"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In-stent (n=1303 lesions)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.219" lower_limit="0.196" upper_limit="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal (n=1086 lesions)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.152" lower_limit="0.125" upper_limit="0.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal (n=1298 lesions)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" lower_limit="0.012" upper_limit="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-segment (n=1308 lesions)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.128" lower_limit="0.099" upper_limit="0.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Gain</title>
        <description>Net Gain = Acute Gain - Late Loss, paired analysis only.</description>
        <time_frame>On day 0 after procedure</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Net Gain</title>
          <description>Net Gain = Acute Gain - Late Loss, paired analysis only.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1548"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1850"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In-stent (n=1300 lesions)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.536" lower_limit="1.504" upper_limit="1.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-segment (n=1305 lesions)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.269" lower_limit="1.235" upper_limit="1.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Success</title>
        <description>Acute Success: Procedural Success (Subject Level Analysis): Stent implant procedure was considered successful when all of the following criteria were met:
Stent was successfully delivered to the intended location
Stent was successfully deployed at the intended location
Stent delivery system was withdrawn without any issue Stent implantation procedure was considered successful in 99.94% of the stents. There was no stent adjudicated as procedure failure.</description>
        <time_frame>On day 0 (Immediately post-index procedure)</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Success</title>
          <description>Acute Success: Procedural Success (Subject Level Analysis): Stent implant procedure was considered successful when all of the following criteria were met:
Stent was successfully delivered to the intended location
Stent was successfully deployed at the intended location
Stent delivery system was withdrawn without any issue Stent implantation procedure was considered successful in 99.94% of the stents. There was no stent adjudicated as procedure failure.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>percentage of stents</units>
          <param>Number</param>
          <units_analyzed>stents</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2009"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>stents</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Death (Cardiac Death, Vascular Death, or Non-cardiovascular Death)</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Death (Cardiac Death, Vascular Death, or Non-cardiovascular Death)</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Death (Cardiac Death, Vascular Death, or Non-cardiovascular Death)</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>From 1 to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Death (Cardiac Death, Vascular Death, or Non-cardiovascular Death)</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Death (Cardiac Death, Vascular Death, or Non-cardiovascular Death)</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>From 2 years to 3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Death (Cardiac Death, Vascular Death, or Non-cardiovascular Death)</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarctions (MI)</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarctions (MI)</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarctions (MI)</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>From 1 year to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarctions (MI)</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarctions (MI)</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>From 2 years to 3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarctions (MI)</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>From 1 year to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>From 2 years to 3 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>From 1 Year to 2 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>From 2 Years to 3 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death and All MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death and All MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death and All MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>From 1 Year to 2 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death and All MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death and All MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>From 2 Years to 3 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death and All MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
        <time_frame>From 1 Year to 2 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
        <time_frame>From 2 Years to 3 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death, Target Vessel Myocardial Infarction (TVMI) and TLR</title>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death, Target Vessel Myocardial Infarction (TVMI) and TLR</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death, Target Vessel Myocardial Infarction (TVMI) and TLR</title>
        <time_frame>From 1 Year to 2 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death, Target Vessel Myocardial Infarction (TVMI) and TLR</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death, Target Vessel Myocardial Infarction (TVMI) and TLR</title>
        <time_frame>From 2 Years to 3 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death, Target Vessel Myocardial Infarction (TVMI) and TLR</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
        <time_frame>From 1 Year to 2 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
        <time_frame>From 2 Years to 3 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death, All MI and Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths and All MI</title>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths and All MI</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths and All MI</title>
        <time_frame>From 1 Year to 2 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths and All MI</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths and All MI</title>
        <time_frame>From 2 Years to 3 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths and All MI</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths, All MI and All Revascularization</title>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths, All MI and All Revascularization</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths, All MI and All Revascularization</title>
        <time_frame>From 1 Year to 2 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths, All MI and All Revascularization</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths, All MI and All Revascularization</title>
        <time_frame>From 2 Years to 3 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths, All MI and All Revascularization</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths, TVMI and TLR</title>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths, TVMI and TLR</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths, TVMI and TLR</title>
        <time_frame>From 1 Year to 2 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths, TVMI and TLR</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths, TVMI and TLR</title>
        <time_frame>From 2 Years to 3 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths, TVMI and TLR</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths, TVMI and CI-TLR</title>
        <time_frame>Post Procedure to 1 Year</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths, TVMI and CI-TLR</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths, TVMI and CI-TLR</title>
        <time_frame>From 1 Year to 2 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths, TVMI and CI-TLR</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1921"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Deaths, TVMI and CI-TLR</title>
        <time_frame>From 2 Years to 3 Years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V / PROMUS Stent</title>
            <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Deaths, TVMI and CI-TLR</title>
          <population>The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>XIENCE V / PROMUS Stent</title>
          <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
XIENCE V / PROMUS stent: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Abbott Categories</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="910" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Mild: bleeding that is not moderate nor severe</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Moderate: bleeding that requires blood transfusion but does not result in hemodynamic compromise</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Severe/Life Threatening (either intracranial hemorrhage or bleeding that causes hemodynamic compromi</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal stress test</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Angina-equivalent symptoms</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Arrhythmia of unknown reason</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Atrial arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Cardiac: other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Elevated cardiac enzymes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="244" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Stent Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Valve disorder</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary/liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease, diarrhea, nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Other gastro-intestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Pancreatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab Test (Non-cardiac):Abnormal CBC with differentials</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Abnormal Lab Test (Non-cardiac):Abnormal liver enzymes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Abnormal Lab Test (Non-cardiac):Abnormal other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Death of unknown reason</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Eye/ear/nose/throat disorder</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Non cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>General/Musculoskeletal/ Connective: Other</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title vocab="Abbott categories">Outcome to Death</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Weakness/fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction to antiplatelet Agent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Allergic Reaction to contrast</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Local infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Wound infection/abnormal healing</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Hyper/hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Thyroid disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ache/ myalgia/ pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Bone or joint injury/disorder</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Cancer and tumour: other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Malignant</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Headache/migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Nerve/Psychiatric Disorders : Other</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Stroke/CVA</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Syncope/fainting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genito-urinary and renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease (COPD)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Interstitial pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Respiratory System: other</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Respiratory insufficiency/failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>skin/subcutaneous disorder: other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Abrupt closure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>No/slow reflow</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Peripheral arterial disease</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease (PVD)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Thrombosis – non stent</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Vascular: other</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Abbott Categories</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Mild: bleeding that is not moderate nor severe</sub_title>
                <description>Bleeding</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Moderate: bleeding that requires blood transfusion but does not result in hemodynamic compromise</sub_title>
                <description>Bleeding</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal stress test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Angina-equivalent symptoms</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Arrhythmia of unknown reason</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Elevated cardiac enzymes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Stent Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary/liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Gastro-intestinal disorder (e.g. GERD, diarrhea, nausea)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>General/Musculoskeletal/ Connective : Other</sub_title>
                <description>Except bone or joint injury/disorder and Non cardiac chest pain.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction:To antiplatelet Agent</sub_title>
                <description>Allergic Reaction</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infection/abnormal healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <description>Metabolism/endocrine</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Hyper/hypoglycemia</sub_title>
                <description>Metabolism/endocrine</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone or joint injury/disorder</sub_title>
                <description>Systemic/musculoskeletal/connective tissue disorder</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign</sub_title>
                <description>Cancer and Tumor</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Malignant</sub_title>
                <description>Cancer and Tumor</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nerve/psychiatric disorders : Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genito-urinary and renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Respiratory/Pulmonary disorders : Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Jailing of side branch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>No/slow reflow</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Peripheral artery disease (PAD)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Spasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Thrombosis – non stent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David R Rutledge</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>(408) 845-3820</phone>
      <email>david.rutledge@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

